Literature DB >> 26668083

Predictors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer.

Eisar Al-Sukhni1, Kristopher Attwood2, David M Mattson3, Emmanuel Gabriel4, Steven J Nurkin4.   

Abstract

BACKGROUND: Some patients with rectal cancer who receive neoadjuvant chemoradiotherapy (nCRT) achieve a pathologic complete response (pCR) and may be eligible for less radical surgery or non-operative management. The aim of this study was to identify variables that predict pCR after nCRT for rectal cancer and to examine the impact of pCR on postoperative complications.
METHODS: A retrospective review was performed of the NCDB from 2006 to 2011. Patients with rectal cancer who received nCRT followed by radical resection were included in this study. Multivariable analysis of the association between clinicopathologic characteristics and pCR was performed, and propensity-adjusted analysis was used to identify differences in postoperative morbidity between pCR and non-pCR patients.
RESULTS: A total of 23,747 patients were included in the study. Factors associated with pCR included lower tumor grade, lower clinical T and N stage, higher radiation dose, and delaying surgery by more than 6-8 weeks after the end of radiation, while lack of health insurance was linked with a lower likelihood of pCR. Complete response was not associated with an increased risk of major postoperative complications.
CONCLUSIONS: Several clinical, pathologic, and treatment variables can help to predict which patients are most likely to have pCR after nCRT for rectal cancer. Awareness of these variables can be valuable in counseling patients regarding prognosis and treatment options.

Entities:  

Mesh:

Year:  2015        PMID: 26668083      PMCID: PMC5295136          DOI: 10.1245/s10434-015-5017-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  56 in total

1.  Clinical prediction of pathological complete response after preoperative chemoradiotherapy for rectal cancer.

Authors:  Jung Wook Huh; Hyeong Rok Kim; Young Jin Kim
Journal:  Dis Colon Rectum       Date:  2013-06       Impact factor: 4.585

2.  Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization.

Authors:  Angelita Habr-Gama; Rodrigo O Perez; Gregory Wynn; John Marks; Hermann Kessler; Joaquim Gama-Rodrigues
Journal:  Dis Colon Rectum       Date:  2010-12       Impact factor: 4.585

3.  Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer.

Authors:  Salvatore Pucciarelli; Carlo Capirci; Urso Emanuele; Paola Toppan; Maria Luisa Friso; Gian Maria Pennelli; Giovanni Crepaldi; Lara Pasetto; Donato Nitti; Mario Lise
Journal:  Ann Surg Oncol       Date:  2005-02-04       Impact factor: 5.344

4.  Prognostic factors for postoperative morbidity and tumour response after neoadjuvant chemoradiation followed by resection for rectal cancer.

Authors:  Annefleur E M Berkel; Dankert P Woutersen; Job van der Palen; Joost M Klaase
Journal:  J Gastrointest Surg       Date:  2014-06-18       Impact factor: 3.452

5.  Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer.

Authors:  D A M Sloothaak; D E Geijsen; N J van Leersum; C J A Punt; C J Buskens; W A Bemelman; P J Tanis
Journal:  Br J Surg       Date:  2013-03-27       Impact factor: 6.939

6.  Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer.

Authors:  Matthew F Kalady; Luiz Felipe de Campos-Lobato; Luca Stocchi; Daniel P Geisler; David Dietz; Ian C Lavery; Victor W Fazio
Journal:  Ann Surg       Date:  2009-10       Impact factor: 12.969

7.  Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-analysis of Published Studies.

Authors:  Fausto Petrelli; Giovanni Sgroi; Enrico Sarti; Sandro Barni
Journal:  Ann Surg       Date:  2016-03       Impact factor: 12.969

8.  Impact of interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer on surgical and oncologic outcome.

Authors:  Wei-Gen Zeng; Zhi-Xiang Zhou; Jian-Wei Liang; Zheng Wang; Hui-Rong Hou; Hai-Tao Zhou; Xing-Mao Zhang; Jun-Jie Hu
Journal:  J Surg Oncol       Date:  2014-05-29       Impact factor: 3.454

9.  Intensity-modulated radiation therapy for rectal carcinoma can reduce treatment breaks and emergency department visits.

Authors:  Salma K Jabbour; Shyamal Patel; Joseph M Herman; Aaron Wild; Suneel N Nagda; Taghrid Altoos; Ahmet Tunceroglu; Nilofer Azad; Susan Gearheart; Rebecca A Moss; Elizabeth Poplin; Lydia L Levinson; Ravi A Chandra; Dirk F Moore; Chunxia Chen; Bruce G Haffty; Richard Tuli
Journal:  Int J Surg Oncol       Date:  2012-08-13

10.  Clinical predictive factors of pathologic tumor response after preoperative chemoradiotherapy in rectal cancer.

Authors:  Chi Hwan Choi; Won Dong Kim; Sang Jeon Lee; Woo-Yoon Park
Journal:  Radiat Oncol J       Date:  2012-09-30
View more
  30 in total

1.  Systemic Inflammatory Markers Combined with Tumor-Infiltrating Lymphocyte Density for the Improved Prediction of Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer.

Authors:  Ryuichiro Sawada; Takashi Akiyoshi; Yusuke Kitagawa; Yukiharu Hiyoshi; Toshiki Mukai; Toshiya Nagasaki; Tomohiro Yamaguchi; Tsuyoshi Konishi; Noriko Yamamoto; Masashi Ueno; Yosuke Fukunaga
Journal:  Ann Surg Oncol       Date:  2021-04-19       Impact factor: 5.344

2.  Value of combined multiparametric MRI and FDG-PET/CT to identify well-responding rectal cancer patients before the start of neoadjuvant chemoradiation.

Authors:  Niels W Schurink; Lisa A Min; Maaike Berbee; Wouter van Elmpt; Joost J M van Griethuysen; Frans C H Bakers; Sander Roberti; Simon R van Kranen; Max J Lahaye; Monique Maas; Geerard L Beets; Regina G H Beets-Tan; Doenja M J Lambregts
Journal:  Eur Radiol       Date:  2020-02-07       Impact factor: 5.315

3.  Relations of Changes in Serum Carcinoembryonic Antigen Levels before and after Neoadjuvant Chemoradiotherapy and after Surgery to Histologic Response and Outcomes in Patients with Locally Advanced Rectal Cancer.

Authors:  Gota Saito; Sotaro Sadahiro; Takashi Ogimi; Hiroshi Miyakita; Kazutake Okada; Akira Tanaka; Toshiyuki Suzuki
Journal:  Oncology       Date:  2017-12-22       Impact factor: 2.935

4.  The Impact of Pathologic Complete Response in Patients with Neoadjuvantly Treated Locally Advanced Rectal Cancer-a Large Single-Center Experience.

Authors:  A M Dinaux; R Amri; L G Bordeianou; T S Hong; J Y Wo; L S Blaszkowsky; J N Allen; J E Murphy; H Kunitake; D L Berger
Journal:  J Gastrointest Surg       Date:  2017-04-06       Impact factor: 3.452

5.  UEG Week 2020 Poster Presentations.

Authors: 
Journal:  United European Gastroenterol J       Date:  2020-10       Impact factor: 4.623

6.  Pathologic Complete Response Despite Nodal Yield Has Best Survival in Locally Advanced Rectal Cancer.

Authors:  Sumana Narayanan; Kristopher Attwood; Emmanuel Gabriel; Steven Nurkin
Journal:  J Surg Res       Date:  2020-03-12       Impact factor: 2.192

7.  Association of Adjuvant Chemotherapy With Overall Survival in Patients With Rectal Cancer and Pathologic Complete Response Following Neoadjuvant Chemotherapy and Resection.

Authors:  Patricio M Polanco; Ali A Mokdad; Hong Zhu; Michael A Choti; Sergio Huerta
Journal:  JAMA Oncol       Date:  2018-07-01       Impact factor: 31.777

8.  The clinical significance of simple endoscopic scoring of patients with rectal cancer after concurrent chemoradiotherapy.

Authors:  Ji Hun Choi; Jae Hyun Kim; Do Hyeong Lee; Sanghwan Byun; Kyoungwon Jung; Sung Eun Kim; Won Moon; Moo In Park; Seun Ja Park
Journal:  J Gastrointest Oncol       Date:  2019-12

9.  Significant Association Between XRCC1 Expression and Its rs25487 Polymorphism and Radiotherapy-Related Cancer Prognosis.

Authors:  Li Gong; Ming Luo; Renhuang Sun; Li Qiu; Chunli Chen; Zhiguo Luo
Journal:  Front Oncol       Date:  2021-05-19       Impact factor: 6.244

10.  Radiomic signature of the FOWARC trial predicts pathological response to neoadjuvant treatment in rectal cancer.

Authors:  Zhuokai Zhuang; Zongchao Liu; Juan Li; Xiaolin Wang; Peiyi Xie; Fei Xiong; Jiancong Hu; Xiaochun Meng; Meijin Huang; Yanhong Deng; Ping Lan; Huichuan Yu; Yanxin Luo
Journal:  J Transl Med       Date:  2021-06-10       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.